“We are at an inflection point regarding treatment of obesity,” said Robert Kushner, MD, MS, Northwestern University Feinberg School of Medicine.
In January 2023, Robert Kushner, MD, MS, professor of medicine and medical education at Northwestern University Feinberg School of Medicine, and Ania Jastreboff, MD, PhD, professor of medicine and pediatrics at Yale School of Medicine, published a review of glucagon-like peptide 1 (GLP-1) receptor agonists and the future of nutrient-stimulated hormone-based antiobesity therapeutics.
This year, at the American Society for Preventive Cardiology (ASPC) 2024 Congress on CVD Prevention, Kushner presented on the “new era” of obesity management, emphasizing the therapeutic targeting of the gut-brain axis with GLP-1 and glucose-dependent insulinotropic polypeptide (GIP)–mimicking hormones. According to Kushner, these advanced treatments not only facilitate significant weight loss, but also offer broader health benefits, such as improved cardiovascular outcomes and enhanced organ function.
Transcript
What are you focusing on in your ASPC Congress session on GLP-1 agonists for obesity management?
In my session, I'm going to be highlighting a major theme, and that is that we are at an inflection point regarding treatment of obesity, and I qualify the inflection point by 3 major areas. One is that we are shifting the therapeutic target of obesity—I actually call that a paradigm shift—and we're shifting it to the gut-brain axis, which we really haven't seen before. What we're doing now is mimicking the naturally occurring gut hormones, such as GLP-1 or GIP, and give them back as synthesized versions at hyperpharmacological levels to cause significant benefits. The second major area is that we have highly effective medications that are born out of these mimicking hormones, such as semaglutide or tirzepatide, again highly effective, more than we've seen before. And the last is that these incretin hormones like GLP-1 or GIP have pleiotropic effects, and that is beyond weight loss, they have effects in multiple organs of the body, which is improving the overall health of our patients that are living with obesity.
What are some major updates to the obesity management landscape you’ve seen in the past year, especially around nutrient-stimulated hormone-based antiobesity therapeutics?
Building off of these highly effective medications that have pleiotropic effects, what we're seeing now published in highly reputable journals which we haven't seen before—like New England Journal of Medicine, Lancet, and so forth—are the effects of these medications on reducing cardiovascular disease and outcomes; improving the symptoms of individuals with obstructive sleep apnea; improving kidney function in those with overweight, obesity, and diabetes; improving the risk of developing diabetes; and lastly, improving what we call now metabolic [dysfunction]–associated steatotic liver disease or MASLD. These are these weight-independent effects that are really involving the health of our patients that we treat and we're getting a lot of play and so many more articles, they're going to be coming out soon as well.
AI's Role in Oncology: Supporting, Not Replacing, Health Care Providers
January 9th 2025In this second half of our interview with Vanderbilt University Medical Center’s Travis Osterman, DO, MS, FAMIA, FASCO, he discusses opportunities for advancing the smart use of artificial intelligence (AI) in cancer care.
Read More
Managed Care Cast Presents: BTK Inhibitors in Treatment-Naive Patients With CLL and MCL
December 26th 2024A trio of experts discuss the treatment of chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL) with Bruton tyrosine kinase (BTK) inhibitors, including cost considerations.
Listen
Leveraging AI and Community Health Workers to Boost Trial Access
January 4th 2025In this second part of our interview with Kasey Bond, MPH, NYU Langone Health, we discuss the contributions of community health workers to increasing clinical trial access and how technology—artificial intelligence (AI), in particular—can help to facilitate the process.
Read More
HS Treatment Goals: Better Quality of Life, Not Just Control
January 3rd 2025For part 3 of our discussion with Chris Sayed, MD, we tackle several important topics in the hidradenitis suppurativa (HS) and inflammatory disease space: patient quality of life, medication and treatment goals, and the possibility of a cure.
Read More